ORION CLINICAL SERVICES LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. ORION CLINICAL SERVICES LIMITED · parent
   1. Orion Santé SARL 100% · France · Clinical research
   2. Orion Clinical Services (Australia) Pty Ltd 100% · Australia · Clinical research
   3. Orion Clinical Services, Inc 100% · USA · Clinical research
   4. Orion Clinical Research Services GmbH 100% · Germany · Clinical research
   5. Orion Clinical Services Hungary Kft 100% · Hungary · Clinical research
   6. Simbec-Orion (POL) Sp. z o.o. 100% · Poland · Clinical research

Significant events

• “The company is part of a group of companies, the ultimate parent company being Simbec-Orion Holdings Limited, a company incorporated in Jersey and controlled by CBPE Capital.”
• “The company usually invoices clients in the currency of their choice, typically Sterling, Euros or US Dollars. With a significant proportion of the company's costs in the same currency as the revenue generated, there is a partial natural currency hedge.”
• “The company conducts clinical studies with drugs which are still in development. Consequently, there is always a risk that a study may be terminated early due to the occurrence of unexpected adverse events where the drugs on test are ineffective, or due to changes in clients' investment priorities.”
• “During the year, the company charged £11.8m (2023: £11.5m) to the statement of comprehensive income in respect of research and development and recognised a gross R&D tax credit of £2.4m (2023: £2.1m).”
• “The RCF facility expired in January 2024.”
• “Administrative expenses include exceptional costs of £643,372 (2023: £nil) relating to redundancy costs incurred during the reorganisation of the group headed by S-O Mid Corp Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +12.9%

  £17,451,278 → £19,709,077

• Cash

  +117.8%

  £1,411,380 → £3,074,109

• Net assets

  +26.3%

  £2,738,627 → £3,459,221

• Employees

  -13.7%

  168 → 145

• Operating profit

  +18.8%

  £681,310 → £809,525

• Profit before tax

  +18.8%

  £681,310 → £809,525

• Wages

  -6.2%

  £9,635,206 → £9,034,334

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers